[
  {
    "id": "90f0bae10920066c4f02931fccdd2624",
    "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
    "date": "2025-09-05T18:56:15.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
    "company": "FDA Releases Complete Response Letter on Declining MDMA",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "600d153f3a65e5b719345b193cf0ffca",
    "title": "FDA to publish CRLs in real time; PEPFAR to distribute Gilead’s Yeztugo",
    "link": "https://www.biopharmadive.com/news/fda-complete-response-letters-gilead-pepfar-yeztugo-ac-immune-layoffs/759306/",
    "date": "2025-09-05T15:15:00.000Z",
    "dateFormatted": "05/09/2025",
    "source": "BioPharma Dive",
    "sourceCategory": "trade",
    "summary": "The FDA also unveiled a batch of 89 previously unpublished complete response letters, including rejection notices to Capricor and Replimune.",
    "company": "Unknown Company",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "b9dd2f8cf67297a8d9e5daf4771895e2",
    "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
    "date": "2025-09-05T02:37:30.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
    "company": "Unknown Company",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "e594d4be1fa880121240843648ec8211",
    "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
    "date": "2025-09-05T00:09:00.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
    "company": "MDMA",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "3903ec6d5750072d9d02c8693c4736db",
    "title": "FDA publishes drug rejection letters for ongoing applications for the first time",
    "link": "https://endpoints.news/fda-for-the-first-time-publishes-drug-rejection-letters-for-ongoing-applications/",
    "date": "2025-09-04T19:20:52.000Z",
    "dateFormatted": "04/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "On Thursday, the FDA finally did what several prior agency commissioners only promised to do: publish redacted complete response letters for drugs that are still under consideration by the agency despite the initial rejection.  ...",
    "company": "Unknown Company",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 2
  },
  {
    "id": "990d9ccf7dffaadddc56b1e2727efae1",
    "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
    "date": "2025-09-04T16:10:06.000Z",
    "dateFormatted": "04/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
    "company": "Unknown Company",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "ce6a56b732279eb4723932a35e3df836",
    "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
    "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
    "date": "2025-09-04T15:41:33.000Z",
    "dateFormatted": "04/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
    "company": "Astellas",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "a387f952dbc047cb286f23729bc3b4e1",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89",
    "date": "2025-09-04T13:23:32.000Z",
    "dateFormatted": "04/09/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.",
    "company": "FDA Announces Real",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 1
  },
  {
    "id": "20454a1bf18d91b8a792959c5d5b450f",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNVFdoVlBOSnBCeWZqcUs5by1MMXJwU29qMUlEelRwRFZXYk0yUUlrQmpPSmUtb0ZkNVU0SlRHeVk0bjNjbDRibVNKeTRyX3NmMU41UjREQ1NwQ1N4MC04WXBTRDZwelAydml6Q0RPV2hkME5paWxEWXlFOVR1dXBxWGlZRG9HMVVFeXJkT0NaOUdXSkNjQW90OTRVemszYm9BcUlsNmNXX01xRXBJZzhyX0dnNEltRkVtUnFoakxrSFdWS20yMFZvVzJyOG1BUTM3bE5QMEcyVVFnOU1NenM4Uw?oc=5",
    "date": "2025-09-04T04:00:00.000Z",
    "dateFormatted": "04/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "warning_letter",
    "summary": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89  fda.gov",
    "company": "FDA Announces Real",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "6f9c48d566c48a1628fb77e08a7a7746",
    "title": "FDA Issues Complete Response Letter to Outlook Therapeutics - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVzdiX0sxNnREVi0tSHBPaDhrZngtQkRYRnE4c1VKVFRzcHVtSVZRN3l2TW53a19QeUlEdlROaHd3cWxITVdFODM2bWV4LW5mclVYLWFHNlRIYnpTSHpMUkJ6ZjFDMG5DSVd6ZDk1V2R3LUg1ZzE1eFFfUHNpVFRUY01POTVveHRtTl9lWlczdUZkNHVRd0o0cFptT3JJSnpBMWdCSllEWEI5Sk4wX2lYZA?oc=5",
    "date": "2025-09-02T21:45:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to Outlook Therapeutics  TipRanks",
    "company": "Outlook",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "69ab508957df49afd34b3c5e074aa215",
    "title": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZmF0a0F4VGs4MjA3QlpBRGJxcjlzODF4dlN6XzVYbnN4OElBWFdxNUpNOTBvZG9ya2JWWWVDV1VfdjNyUkpLSW41QmYxSGdGSWZESzA3emJGQUROcnpfU0JKa3RvT1JHN0JLaEc0SlJBSHlSU1ZwcHZZcFpfVHd6Q3NfYmxzSkh1?oc=5",
    "date": "2025-09-02T17:28:42.000Z",
    "dateFormatted": "02/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter  Yahoo Finance",
    "company": "Unknown Company",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "1e5c75709e0a5ead11d28f285a1e7b54",
    "title": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma - MarketScreener",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcjNUVWlfM2wxTnQ1RTlLU0wyYVAtZWNiQnpITDN0Z1dIeTNUS3ZYTXY4SnppYmpReWdpWUI5TlgzUWtMQVVMd0tzVGFYTUE3ZThyMjZPWEM4ZWhDMGJHajZrZDJ1LTZ0VUJNUlZkRDhCWmFOakVjZVJzY1BRTG04U3B5WEl4MlZYSzFiWWdLUmtiVEZabXZ6cHZ3ZmNVTjFTanNQTktvUExmbnJaa3RDUUFCN3A2Q3pxQlJYRE1HVVprdFFVZlVPYldCSm1KaUlnQ1FIQU55aw?oc=5",
    "date": "2025-09-02T12:56:17.000Z",
    "dateFormatted": "02/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma  MarketScreener",
    "company": "Treat",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "697634c3cb7acc1128dc756458bb740e",
    "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
    "date": "2025-09-02T12:44:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
    "company": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "4c3a9f4c519e1aaa741c4c40ae669ccf",
    "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
    "company": "Outlook",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "0b29f4ba31eaa7984e2a5ba6ade2f3f9",
    "title": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC - Urology Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTENaRm5KN0ZXT2V2dUpYWWRiTU5RSDA1R18xcU5IcWplcms4b0VxYU8zTllCQUJJU2RJZDNCWGxGS0VUZXhPMGEwTmV0M2gxbXRBMHZFTHlJVC1iZzhTWXlkYnVySWJtZUI1aVN5eFp1R0JGOVhFRlkxcTFIaTU1LUJfaUY2VUxPWXJkd3RqYWVXdk10U3Uya2lvYnUwNWRvTVh6Wm03QQ?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC  Urology Times",
    "company": "FDA issues complete response letter for 89Zr",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "2baa7fe8d43d843fc7a9cdc1730fc294",
    "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
    "company": "Outlook",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "2a0c82a7b56c7c79747aa0eecc276183",
    "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
    "company": "Telix stock plunges after FDA issues Complete Response Letter",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "aefc0a2136acc5d84217b86ad565292b",
    "title": "FDA received complete response letter from FDA for Columvi in DLBCL - PPF Group",
    "link": "https://news.google.com/rss/articles/CBMioAJBVV95cUxNWXhMcURoaGVLOVlfV2lBN01uc2VuRTU1TVlxcE1kdkFQekNETjRFRW83M3huT3lIRFMxY0xCOWtCVzFKd0JSczc2TV94bXN5TlVWWjVKQm5nMkUzRWhwdDZPYWdrZ3l0d2JUYWFSQXNCeE44aTNQTGVBRG5vVWhvRExPUnhUMzBibUFJTFIyWGFjOGpGblR0Y0hHUy1oTDQ3RjdTY29jS0VzX1hzWF9QYktyaHlPR2RmMGVCX0xGSVRMNC1iUjlacnRlZndmeG5qVVl6ZFdMRkRBUGhpd3BFbjhhWVZWQlRoNFloYWYyQ25jTUZRZXhkSGFzY0ljODVxbjBCZHhKN2pCSmloR3oxSzdxRXJCbGNlaXVwOGVlNnU?oc=5",
    "date": "2025-08-27T22:51:27.000Z",
    "dateFormatted": "27/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA received complete response letter from FDA for Columvi in DLBCL  PPF Group",
    "company": "FDA received complete response letter from FDA for Columvi in DLBCL",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "fc52320fed3dd7784110b99b937a0bf0",
    "title": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHMyWmRFQ0VxOUE2VW9zdkg3MzQ1S0NnWldQNTcxeV9UM3RERjNKNFZSdzFFZnF2OHRHTThPWDN5cm40Nk1STTNoTkZWUTNwc1BNbkRDTnRaT0F0VzJWUVVTbjMtWEtKanVjRnkwNHZ2ZVM2S1BpUFZhS3FjNnAyVElJRXozdkxGanp4ZHdOdmxQS0FjbEVSaFVvVnk3eUJiYzlURGZEbFh4WW5p?oc=5",
    "date": "2025-08-21T07:00:00.000Z",
    "dateFormatted": "21/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro  geneonline.com",
    "company": "Unknown Company",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "b4f1c291ccb309df5913d394b9b09d2d",
    "title": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdEhEZjBoaVlxbHNHc0drWWxWdzd6cVBIdkhNd2FYeXpyZ0NISnI5Y2VVT3FqSGlVOUdIZ3Rqc0hxeUhja1UwSk9QeEFiZjJkbVB3ZlluaVFyMEkzendEZC10UWZNLWpGTzFkYXpKSmxDMnE0cUdtV05XSzJCRXZvWFEzVUxKUVJIemFJVnNNUHhOX0NINmxiRnFGX1Y2ckF5dmVsX1phVmphbkFtbmU2MW5LTURFbkdVMzh5UmhXYTZLZHR6VG04UUZkSlhwUUR3REZuU29EMGR2RnhMMlRNX2tlT2FBNDVvS292cnBNUlk2ZWIy?oc=5",
    "date": "2025-08-20T18:08:52.000Z",
    "dateFormatted": "20/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia  geneonline.com",
    "company": "PTC",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "e66824ed54c7a4e9b981727be58f8c39",
    "title": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen - Curetoday",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPNi0yMDRsekFtZmMwZFB3cjdOekF6WGxiUnJPWnBPMU5RQVBkaVZCVlh3SlJKSGgtaXdTcjZraTNJSVpzMXBNUDR5aHJZUlF4YzNQUk85VVpsRFRKNzZmOTFKNWcwc21oeGQ1dkY5UDBpZWdpaUdLbFhBdkdIVkF0VUdfZXd5ek5PQklmM2dQU1Rtb2hQQUE?oc=5",
    "date": "2025-08-20T07:00:00.000Z",
    "dateFormatted": "20/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen  Curetoday",
    "company": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "1497aa7c4cbf64c9c035f7d0ee1006ae",
    "title": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA - Contract Pharma",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPN1Zpanp6WWlzNWUzRnl4NXRpOFdWWVRRRE1laGZZdGRJbDVzWFZ6Q0N5T1F0MkRQbEgwc1FmNzB3X1Jqc1lTa3VEMm1vMExiRUFtNENZRUNabWR4anQzMWJGcXZHcXV5NUI5QjZBQmxINnQxMnJlN0JOTEh2aXJpUGVqczFPTU01N1QtUFdBNjhzNHN1VVlFOTZ0WjdtcUlTSWxBWA?oc=5",
    "date": "2025-08-19T13:56:19.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA  Contract Pharma",
    "company": "Unknown Company",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "9555319419e5bd90505943352e927fb5",
    "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
    "date": "2025-08-19T07:00:00.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
    "company": "PTC",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "7cab5af129025a1de42f61686d406584",
    "title": "PTC Therapeutics Receives FDA Complete Response Letter - MSN",
    "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZmI0WlRSMDNhNURtOWxSbkJrLVY3UFFNODhiTmxEc3NxeTB6VEhVSURFWEh5VUxCTFZKLUJsT2lEZjVlcEhlM3Rpb2htdjdLcnVoLURIcHhxaDcxVFI2YVRtOWNET0Q0OVVEU3ZtQkZVaGpTQWNuUXR2anotbHdpY3ZGTkZzU2V3OGQ2bFoxVDdtaG5CWDgyRnhHRXNkWXJqY2lpVzlKeEc?oc=5",
    "date": "2025-08-19T07:00:00.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "PTC Therapeutics Receives FDA Complete Response Letter  MSN",
    "company": "PTC Therapeutics Receives FDA Complete Response Letter",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "a3bcd45975121bed4a4ba29f7842cfa6",
    "title": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment - Neurology live",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSEJkaW1DYnZ3THRNTWdpc2hNMFh6dXNPUHdFUXoyRjlwWnRQVzZybXNGMmtDOHdsVnA1M0NIU0UxVUlGQTYxLWVIM0FmcGlFMWY2VFlXMTZINVNfRmppWjMxRlY1VWVXUE1GVjJubTRZTEdrOE1GZXNqV1QwbEZLcFBNYTFYTVNRTno5UUhibG04QW5LUUNuTFZTdFcxTERoYWo3Y2tLQ3lvV1ZkS0EzcUY4Ulp5LXd5V0E?oc=5",
    "date": "2025-07-30T07:00:00.000Z",
    "dateFormatted": "30/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment  Neurology live",
    "company": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "add6447f71a5057d1052e3deeadd53c1",
    "title": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeUpKUXVENG1XWnEtZHRPR0ttTkdJOUNidUMwMUJvY3pTY3ctS1VNeUd6Wi1TaS1KVks5REdYTERpcUxmTndpVnk5VGtfd2pqUGZvSUFvT2JJTGxOWHpKczh2LUl5ai1NSG9IV1VsLVg0aHlwRThsOXpVZUFiNlBtVVdRUjJ0Skk0eTRkU0g4d3FGQVJRSnFSLUV4OTVxRDVHOHc?oc=5",
    "date": "2025-07-22T07:00:00.000Z",
    "dateFormatted": "22/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma  CancerNetwork",
    "company": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "3ce5d146cf7179cc30fdbf8a1cb7e08e",
    "title": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOTHUxdXliYVhkdDUzQTJtZFBuN3oxQzlub3FHaVVtclNlOHQtTHNSdWNPYzhiWXdST2V1VnlMSlBmLVdvSFEwLUsxMXk4WTgzUkE3N1ZSOUp6Mk1tTnZCb0tLY1RITmRoY3YzdS1PVkdBVW5nYkJFV1dDdVdFNzFhWFhSX2QzQ3gxa21vMEhSYWJfZWREMFZRckN2ZFJaTmNGZ01jNHhXc0NIaEZuM0RieV80dnFpZmFNM2J5MHRLODdJYnBJMi1EeDQ5aWs2ZUJ4WW80bkxUaw?oc=5",
    "date": "2025-07-22T07:00:00.000Z",
    "dateFormatted": "22/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment  geneonline.com",
    "company": "Replimune",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "2bf6fe0a74e9530abc32e11d05ea8289",
    "title": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZXlhSFNScVd3dFNhSDBQemMyMVpNUExDeXRYNDlYeFNhZ1F5RGlFcmhPbURGX05tZUhkNFpNdVVrYzRQWnpFS0pyZFFabnNZUXRjNzdRazBZdmV4RS1ZLVFUNFVlbjI1ZVZTQ1RZTzJ3NU9hbzZJZ1dDZ1lremdyUENyU2tlRkZwSVNsTHJweWlXLWtXRVZjRVNSYnNMVW1xTUFMZXlHZllZVHFWR3c4MkptbFpjTGM?oc=5",
    "date": "2025-07-21T07:00:00.000Z",
    "dateFormatted": "21/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy  Targeted Oncology",
    "company": "Unknown Company",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "a5d2830f004982dba0d3e308e6fd0a68",
    "title": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOEp5QUp6MFBYajNKQlptc0lpeWc2MGZYb3E1ckR5MW1GUUhDS2w0TWhWdjFpeVpUbWh3THZPRWJaeDZQWFloem5sZnJUaHh1cTFtWDd4dnJBb2h3MTdWTDBHVnd6cjdtREt0MGFiWjJWcEF5dldvajV5ZlFyQjRKRDBxYTNtUGg3ZHljdnBhdEo5UmFibE1CcVFnNFVBaWhnaHc?oc=5",
    "date": "2025-07-18T07:00:00.000Z",
    "dateFormatted": "18/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL  Pharmacy Times",
    "company": "FDA Issues Complete Response Letter for Glofit",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "86f5dfcf877f324fa6dcb78d361b10db",
    "title": "Ultragenyx receives complete response letter for UX111 BLA - Pharmaceutical Technology",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVUszb2g2NjVsalpmZlZPTmpybFNBVHBiWFRvNHY3NVJhRm1LaTNiMkdjTklkMndSWmFUMDFFTkt6ZXFNYU1ZYkM5QzZEa2NCN1g0MzlmLVRaN1VYdVdCbkdOVzlJRlBXYUVjM3U5Yk5WbEFVVl9KV0NZZjkwSkpMQWc4UDVkekJDUmRTNVFqWllYTHM?oc=5",
    "date": "2025-07-14T07:00:00.000Z",
    "dateFormatted": "14/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx receives complete response letter for UX111 BLA  Pharmaceutical Technology",
    "company": "Ultragenyx",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "521a0ccbc7fae49239acb9ef3e5ff520",
    "title": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNk02ME02b1NUMHltNGRvNHl4eTRVcTBsZzVVc1NXVEFMX1RCN1lZczg4T2NDNm13VmxWWGpUdFhGNk1rSmlMNS1NcHkxZEREdk5sZ1lwcU9hV2NhQTg4RUo0WGxTLWdZYk1zdm1Jb1FGS0hxRXB1Vi1Kd3ZjVzhxeWQtVlFxeHliZ1FjOTZPVi16eXdFMzJlQmRMRjVpNjhNc0l1aC03T1hPbE43UjBhejRrQXRRNnFITF84TXpEX2haMDJ0?oc=5",
    "date": "2025-07-14T07:00:00.000Z",
    "dateFormatted": "14/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter  Seeking Alpha",
    "company": "Capricor",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "767150bd601dae9e316b7b00b5b78f15",
    "title": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNT0w3NDFEdGlZTG51M1VtMnZhS21xSGlCNjA5U0dTeTZmS01iUDFHbGNvR3R4Szl2LThwcE1ETjVtTmFOUFQ5ZzFZQUdwa3ZSWEZGR2s5YnBOZzVkZHpaNVQ5MHlVRndUaHlCZXRjVXd4cnY0UmhxbVBycjVSX19oaVNKdnI5UmlLQWZwSUllLVBqQ3RvQTNHN3JCUzdxT3M5S0E0X2ZWVEJWelBZR3Fyek9XNUZhcGc?oc=5",
    "date": "2025-07-14T07:00:00.000Z",
    "dateFormatted": "14/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application  geneonline.com",
    "company": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "28587d874d993cd193e91f21b6bef8b3",
    "title": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbF8zbDVUalRyb19zVnJOMmMxWVZWc1U3UEgtRWpWTHhUOTVzemwyQ3A3Ykw0dHlqTl92VWVRWkphZ3ZaUVEwVXd6RHIxSFZKbUw1ZDNRN0d6b2k2cl9xbmZ6UDVUTDAwcnJ2U0w1XzI4blhzMVlCQjRjX2RlVVE4V0J3bXUzRHhFOExDR1N2V09pWlZ0SU0tRGx0ckJWVDA1STh4QXJIQUdDazFMRFYzTHhObTNLQTQ?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade  Pharmacy Times",
    "company": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "2d14bffec6d13d8211ae76a932ab09c7",
    "title": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy - FirstWord Pharma",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBalJyWmlNZjQzUWxrRFpsVm9XTGhwMlFBWVd6QUw3S280U1JWX0NQbWZVTEEyVVhvVHF6VHBlenJoOTFHTlB2UnhNOHZqSW9Cck5v?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy  FirstWord Pharma",
    "company": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "f9a74b43925fbbd421601069c19dfddd",
    "title": "FDA issues complete response letter for Ultragenyx gene therapy application - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdS1qUDhaaDlELTdWRElCUG1mT0RlNDVLc1ZmSndvNEVMSlk2ZjVoSjk0cENpTV9lRU1SQ1V5SzMwckxLck51N2VkQ3ZkSUFEeTNESjZjLUREOTVaV3VHa3VDOWNfS0VxaXpWTk1pRUdQaWZkdi1BdlRORGRaaWdXeExBWmk5am4xUXBpWkFDNWg5bmZmUTUxeEhMSE1zZUVIS29YWmV2VHB3VnRvOW51WVctODF2dW5iMVBxdzFPcnpyZGUtNk1aSktEYw?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA issues complete response letter for Ultragenyx gene therapy application  Investing.com",
    "company": "FDA issues complete response letter for Ultragenyx gene therapy application",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "71416ef449bfe41908ebbfd0e4054415",
    "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
    "company": "Ultragenyx",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "2dd1d0f45d22c49818f80cf66ffa6ce8",
    "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
    "company": "Ultragenyx",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "e20a147ab55011c0aa7142edaea49555",
    "title": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdV90QmVuOUpBcXoyc01JNWFHYXVRdFktRDBHNndBM09EbmlFOUtrdy1qR1BQSHp2MnN3MUpiNHozZk4yNWphRzFlcjJPSDJXMkd1X1p3QzFsRHp2SzlJMkltbm5zMERJRjcwVlpHSDh4VTRSYkRNTEU5dm0yMUwyWjV1WGNsNFRrcUtUenhiU0Y0THpLMS1PbEphcC1GSnlzLW1sUmpUcGxFTV9qY1ZkdzAyS1QxM2dSRFkyVl9SMFNtWHM?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy  Investing.com",
    "company": "Unknown Company",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "ef91aca42d02ab7b6b0d70f7592e6a20",
    "title": "Just how radical is the FDA's complete response letter move? - pharmaphorum",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOQlpqYUp3SmJZY2JTam1VUGhNdHh3YWFjdXN3OWYxYkhDbnNLWVJqUWoySHpqWnlwdnRlNXJYWGwwclBwOW9NdllJX1c0RWRjaHpleDVpbHlMVkFkM0NxUzA4N0wwU0FUQXNBMWpIWnpWMVV1OUl2U1liY3luODUzQzRUcG9NNmxs?oc=5",
    "date": "2025-07-10T07:00:00.000Z",
    "dateFormatted": "10/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Just how radical is the FDA's complete response letter move?  pharmaphorum",
    "company": "Unknown Company",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "0769fbfb09721c840928e340a934950c",
    "title": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMWtoZlFGel9acHZOWlQyMm9sS3FhYUpjd240RVZRTGY3WmZkNENTZndFSGVfSUx2UWRBcHJybzlyZWZQTHMxZmNRNWZaWTVJeXBRYmhnM3gxTVA2bFBLY1RRLWNtRFF6dTJjdHpsajh4UXE0aU9PeGtjV1Fsclc1QUNTRWNZZG4zRjVzQWFxd1BhQjhWN1pwODNicXY1VERZYWZTMFBheTBuY2FDMVlXZjFwU0dTSnI4RGd5dllFbGZEYjczemlyRXdKMHBRTVotQXVB?oc=5",
    "date": "2025-07-02T07:00:00.000Z",
    "dateFormatted": "02/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia  Pharmacy Times",
    "company": "Manufacturer",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "a9c9c263b72a1c00967ea0691c42a031",
    "title": "Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbWJhY2x1N1FEYVBlMktadHBUWE1mSUpMdVRQa21zWVZ6dG5oZ0t1c1ZhYktWZHdiOTEwTzdGQUNPVFhqT3V4UUhrS1huU0M2czZNOFBoNUlWb0x5ZFBzVFJVUkpOM3lZUDRwMHNydmJSZk1kRzBiWFVBcHZ4OGdvaDloWVJ1bXZic2RjY1Zvclh1MUhZc2p2NjVMVDNET2hPajBoU3lXX3FBTk95MVJCQnQ4dENTaU9JMUFGWjJxbUEwc2xWQWc?oc=5",
    "date": "2025-07-01T07:00:00.000Z",
    "dateFormatted": "01/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Unicycive stock falls as FDA plans complete response letter for OLC  Investing.com",
    "company": "Unicycive stock falls as FDA plans complete response letter for OLC",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "8b4d2c762b12c315381c24ddaea2061a",
    "title": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHNsMWNuaTNURmo2SVJ0MkZwczNsNkREY2g1bG1XRnRZREUyTlFreVZNYXdlNkJYMjZBV3FwQ2twZmQtOHRPUzNvR2tRNVpFbWxVT01paU9VcGFSQjhMblpFZzg3U25iRlNIZGxaQXFVUTBYb1R6dTVrbzYxamZtUERSazFfS2xIY0g5dGR5ekI0RndTM0lyN3pPc2pnTGhPaklOUVJpZ0FfbW04eUNwVW1kMDAxSmh6QnhRYXlkS18?oc=5",
    "date": "2025-06-30T07:00:00.000Z",
    "dateFormatted": "30/06/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect  Fierce Pharma",
    "company": "FDA hits Unicycive with manufacturing",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "ae75b24704a70de2acbc98362e3fb4e2",
    "title": "FDA issues complete response letter for Unicycive’s kidney drug - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNek9uUkVPNnlxOWU1Ykdia3RQaDFUTjVXc1FUeHYwMHBGNENSUVlhR3RZUEFoLWhRZlRzUHVwMVowOV9MV1V2Z3UzWHVqaUhDdkx3bXBWTjhDQkRPb0hibllsVnV4MDJVeC1aWkp0eW9rNVQwcVd5UEtUR1ZPSlh2aW5wLW5JR1hOaER5NnMxZ3JtMllGcmZZaHBhTUhLZ0hET1gycEw2WWhfbXVFVkxURXJqVEx3VXBRS2cw?oc=5",
    "date": "2025-06-30T07:00:00.000Z",
    "dateFormatted": "30/06/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA issues complete response letter for Unicycive’s kidney drug  Investing.com",
    "company": "Unknown Company",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "ff4eae7a5fbcfd05e69fbe2bbf95c447",
    "title": "Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHV4ZmJtTkl4X21OZVFyU0t4VkpBVTFmMWZVS3JSd3BBa1Y3Zzk1OHo3NFNwNldHUjBSU1BoRlhnZWpRWFQ0Y3lDRlYyWk1QVUhlaHZaX0tXbFNyMnFxeTZKMmw2LTBfalF2ZFRQRmdMd19vMklBRkZiQkFjTWZBTGZCbWcta21MNGIzVUpOOXFPT3FzenNrMUJabTNfS3RmWEZ3MzVR?oc=5",
    "date": "2025-06-16T07:00:00.000Z",
    "dateFormatted": "16/06/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Milestone submits response to FDA Complete Response Letter over Cardamyst  Seeking Alpha",
    "company": "Milestone submits response to FDA Complete Response Letter over Cardamyst",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "ebbdc9970e010bf31230af24ad180ba8",
    "title": "TLX101-CDx Given Complete Response Letter for Glioma Imaging - Oncology Nursing News",
    "link": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxQVmIyemZUbEpPZmx3cGNyNTg1blVBQ1hUNEN1R0JXRDlST05aNzVuTTU3ZXJHbW5LREFmdnU0c3pad0lmN0pycnY5ZW0yU2lBLWgtY0R1aHpnbkNLQktHTlp3eW5GSkoxWDdfcm1fcmMxWnVYcGFRdGh0c29kWWNrMWw1NENHS0RKMVFsdTIwV2JmU0NWTUJ0by1QWXp1Qmd6ZmhWYlducDBaYTlkX19UcU41NzN4LUo2MWpKb0FpMUhNTU40aGczVTJOZ2dhZm1GT1VldExRNkhLalMxSk42TXF4WFFFRVA4S0FqZw?oc=5",
    "date": "2025-05-06T07:00:00.000Z",
    "dateFormatted": "06/05/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "TLX101-CDx Given Complete Response Letter for Glioma Imaging  Oncology Nursing News",
    "company": "TLX101",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "3d3776a9a4741e1d83a19c067353bf14",
    "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
    "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
    "date": "2025-04-03T07:00:00.000Z",
    "dateFormatted": "03/04/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
    "company": "Reproxalap",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "3f5c46764dc7fc47be3a7c577bba8f9e",
    "title": "FDA Issues Complete Response Letter for Etripamil for PSVT - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRTF1MV9aZ28xSjc4c2dMQ1ZEaFlqa0tHQUZBMkhnY1R6Y0x6eC1aVnQtVV9rQVpWeFpPOFo4MldTRlgwN3MtMWdJZ1pLVVJsUFBWeFBqejVPQTBkMEdrUDNKYURTeTBaR3RLVlBqdTZmWkJIdWhDMDdiTEIxUDBRNGVfUENPeHJM?oc=5",
    "date": "2025-03-28T07:00:00.000Z",
    "dateFormatted": "28/03/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Etripamil for PSVT  Yahoo Finance",
    "company": "FDA Issues Complete Response Letter for Etripamil for PSVT",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "53b49b96d48d6c09b0ddf9ef5baf43bb",
    "title": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPRWpwOHNXTXU1SnYwOElkLXphQ010LWtqUWFva2Z0bjVLS1p0d0Z1VGpLRnlaUTVFRDZpQWlBME9xZURmaWlGNWdfMTZiMl9KN3FJbTRlbEQzODhXWHMyRnd5cGQ4d2E1N3p4WVQ0a05FQzRES0pZUGtjanpyZDhLMVNSUTZ6V2lQQTZxNkphOEtGMkdlb2Q4?oc=5",
    "date": "2025-01-16T08:00:00.000Z",
    "dateFormatted": "16/01/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD  Targeted Oncology",
    "company": "FDA Issues Complete Response Letter for Tab",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "27714a8be06e46b6decd46f9c87e039a",
    "title": "Complete Response Letter, Warning Letter and Shareholder Lawsuit Follow FDA Data Integrity Findings - JD Supra",
    "link": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQUGhhVWRtUDA3TEtVa0p6VElTMGE1eXNMcl9mMG1fY3FsdU1xSFdIODBGNWdMVlUtekUxUVFDbFVtZmpxVTF5WVdEblE0MTI0aFllWHJ2ZEM0UkhRcWNYRUdwbTlibUlJUzdPMmEwOUFRdWlTVXZGc2VMa0tvS3NaRXhRRHM4SGQwZGc?oc=5",
    "date": "2025-01-15T08:00:00.000Z",
    "dateFormatted": "15/01/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Complete Response Letter, Warning Letter and Shareholder Lawsuit Follow FDA Data Integrity Findings  JD Supra",
    "company": "Complete Response Letter",
    "types": [
      "warning_letter",
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "e98f3bdf0991eebd9c3d975e2a807ce4",
    "title": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWWFneWJYcGkyU3JDOTJtd0s0RERBdGVTenhmRnc3ZEZyWk1jd2V1akNTLU5Ka190WEtVd1NQdHgzTVVxR3NjeVpZWnl0SmtOZ2dkcnhpZHhIMmRNdTlDME1aekJmQkk5SVB4ZE8wclBHd2YzUm5FalY5eDFhamhMY05JUDR4NE8yNkI4enVMZFZTczIxVWhUdlRUMDBqRnFaaFhmdDdXUQ?oc=5",
    "date": "2024-12-21T08:00:00.000Z",
    "dateFormatted": "21/12/2024",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog  Pharmacy Times",
    "company": "FDA Issues Complete Response Letter for Much",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "28103c6d531d0dbca377068904873c04",
    "title": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC - OncLive",
    "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcDhYRTAzSEdTSzI5OGJ5UGFnWGxWMERJME9Vam1vUTdmYkZtNnJua082QVJaQnB1UEEzbWVDVVpaMGJPaWZrZ1o4YnE0aFVWUzBaai1rVGVwLUFQbWFkRkRpaUd6RTA0aG9GUXRnd1NJQlVYSFRrdEFlSVRXdjdEUUpDSzdpZHplT2ljdGlkOXBjNDdndi1tbk1XOWNscWhSUXpwXy1rZkpuRXFMUmQw?oc=5",
    "date": "2024-12-17T08:00:00.000Z",
    "dateFormatted": "17/12/2024",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC  OncLive",
    "company": "Subcutaneo",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "58fa5522fc70f926166fdf91665ef570",
    "title": "US FDA issues Complete Response Letter for avacincaptad pegol intravitreal solution (IZERVAY) - Modern Retina",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNZUhiM1ZrQ20xX0NZb3hEQlZzczhsV04yQlZkdldQMjBzTm94UjBfd3A3TlhjX0xVMGtHWWZzak9ONnBjR1JMTUFqYlpIMW9zNHFLTzRoc3dtV1Fqa05KVlVxckVWUXRSakJTNV9sb2RoWGpEUFpvZjY2TDhMT2tiTjV4TUhJcGNyR2NuSXBDam9mU0VUazVWWlAtRjJMU3A1Ymw1TXZRb21rZXh4Tjc5N2xfUnZpX2hyMXo2WjVEUGMxRjky?oc=5",
    "date": "2024-11-19T08:00:00.000Z",
    "dateFormatted": "19/11/2024",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "US FDA issues Complete Response Letter for avacincaptad pegol intravitreal solution (IZERVAY)  Modern Retina",
    "company": "Unknown Company",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  }
]